跳至主要内容
临床试验/NCT05437926
NCT05437926招募中不适用

A Study to Describe the Effectiveness of Arrhythmia Analysis Software for Screening of Sinus Rhythm, Atrial Fibrillation and Premature Beats in Light skin-and Dark Skin Tone Patients

Huawei Device Co., Ltd1 个研究点 分布在 1 个国家目标入组 102 人开始时间: 2022年4月21日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
102
试验地点
1
主要终点
Number of participants with Sinus rhythm

研究概览

简要总结

The purpose of this study is to describe the Huawei'ssoftware ("Arrhythmia Analysis Software") for the detection of atrial fibrillation, premature beats, and sinus rhythm using photoplethysmography (PPG). Data derived from a wearable device with a PPG sensor (watch or band) in patients with light skin or dark skin tones will be used as an index test. The Huawei software is intended as a pre-screening technology. It should identify candidates who may benefit from further evaluation. The software is not intended to be a diagnostic system.

详细描述

The purpose of this descriptive study is to describe Huawei's arrhythmia analysis software on PPG data collected with a wearable device (smartwatch or smart band) in people of light and dark skin tones. The study will be conducted at a single research center in The Netherlands. The device under investigation is the Arrhythmia Analysis Software. The Arrhythmia Analysis Software processes a signal from the PPG sensor on a wearable device and displays results data on both the wearable device and mobile phone application.

Data generated from this study will be included in licensing/registration applications for the commercialization of the proposed arrhythmia analysis software. The protocol provides a detailed description of the study and data analysis plan and addresses regulatory requirements relating to ethics approvals, protocol deviations, and disclosure of data. The study will be conducted in compliance with the protocol and all applicable regulatory requirements.

This clinical investigation is a descriptive clinical study at a single research center in which the Huawei Arrhythmia Analysis Software is compared with 12-Lead ECG as the gold standard for arrhythmia detection. Analysis of the ECG output data will be performed by independent physicians who will be blinded to the Arrhythmia Analysis Software output. Also, the physicians deriving data from the Arrhythmia Analysis Software are blinded for analysis of the reference test, the 12-lead ECG. The adjudicated ECG output will then be used to validate the Arrhythmia Analysis Software algorithm.

The 12-lead ECG is the standard for early detection and monitoring of cardiac arrhythmias in Europe and has been used as a comparator.

Prior to enrolling the first patient, the sponsor provides training to the study site personnel to ensure that the study site personnel are fully aware of the research process and are skilled in operating the test instruments.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age >18 of any sex;
  • •Wrist circumference 140 mm - 210 mm;
  • •Fitzpatrick skin type 1, 2, 5, or 6 (pre-screening);
  • •Melanin Index (MI) <150 or >350 as measured on the inner arm;
  • •One of the following conditions, based on past 3 months' history or screening electrocardiogram:
  • •Normal sinus rhythm;
  • •Persistent or permanent or onset atrial fibrillation;
  • •Frequent (>5 beats per minute) premature beats or ongoing premature beats;
  • •Willing and able to provide voluntary, written informed consent

排除标准

  • •Patients using pacemakers or implantable cardioverter defibrillators (ICDs);
  • •Patients with atrioventricular block or bundle branch block;
  • •Patients with sinus tachycardia, significant sinus bradycardia, significant sinus arrhythmia, sinus arrest or sick sinus syndrome;
  • •Interpositional premature beats, dual-law premature beats, triple-law premature beats, border premature beats or escape beat heart rhythm patients;
  • •Patients with atrial tachycardia, atrial flutter, ventricular tachycardia, ventricular flutter or ventricular fibrillation;
  • •Patients with a resting heart rate less than 50 times/minute or more than 110 times/minute;
  • •Patients with tremor disease or chorea disease that are difficult to cooperate in completing the examination while remaining still;
  • •Bullous disease or generalized rash, and other patients not suitable for surface electrode recording;
  • •Patients with skin allergies to alcohol;
  • •Patients with skin infectious diseases;
  • •Patients with a history of mental illness or cognitive impairment;
  • •Patients who have participated in other clinical trials that may affect this trial within the past 30 days;
  • •Concomitant medication that might interfere with study results;
  • •Other situations where the researchers consider it inappropriate for a patient to take part in the trial.

结局指标

主要结局

Number of participants with Sinus rhythm

时间窗: During heart rhythm measurement

Number of participants with regular sinus P waves (60 to 100 times per minute), P-P distance difference is less than or equal to 0.12s and PR interval \> 0.12s

Number of participants with Atrial fibrillation

时间窗: During heart rhythm measurement

Number of participants in which the P wave disappears and is replaced by small irregular baseline fluctuations, which vary in shape and amplitude, called f wave; The frequency ranges from 350 to 600 times per minute. The ventricular rate is very irregular, the atrial fibrillation is not treated with drugs, and the atrioventricular conduction is normal, the ventricular rate is usually between 100 and 160 times per minute. The QRS wave morphology is normal. When the ventricular rate is too fast, indoor differential conduction occurs, QRS wave widens and deforms.

Number of participants with Premature atrial beats

时间窗: During heart rhythm measurement

Number of participants where the appearance of P-QRS-T is early. Note that there is a difference between P-QRS and sinus P-wave shape, which is the important point in identifying atrial premature beats. Sometimes the P wave is hidden in the T wave of the previous cardiac cycle, causing the T wave to be deformed. The interval between P and R is normal and must be greater than or equal to 0.12s. This means that ectopic excitement comes from the atrium and passes through the atrioventricular node. Sometimes the P-R interval is prolonged, which is caused by the atrioventricular node interference. The QRS waveform of ventricular depolarization after atrial premature beat is similar to that of normal sinus conduction. However, sometimes QRS appears wide deformation, called premature atrial beat with intraventricular differential conduction; Atrial premature beat compensation intervals are many incomplete

Number of participants with Ventricular premature beats

时间窗: During heart rhythm measurement

Number of participants which have a QRS wave with broad deformity, time limit ≥ 0.12 s; There are secondary ST-T changes (the direction of T wave is opposite to that of QRS wave) and complete compensation intervals. There was no P wave before and after the QRS wave in the excitation ventricle. Agitation reverse conducts agitation at the atrial and produces retrograde P' waves (inverted leads II, III, aVF, upright leads aVR), with three manifestations: * (1) retrograde P' wave preceded QRS, P'R interval \< 0.12 s; * (2) There is no P' wave before and after the QRS wave. * (3) Retrograde P' wave after QRS, RP' interval \< 0.20 s; VPM with complete/incomplete compensation intervals consult the investigator whether atrial and ventricular premature beats can be combined into one diagnostic criterion.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验